AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

AstraZeneca may face a fine of up to $8 million in China over suspected unpaid taxes related to the import of its breast ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over ...

The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help it ...

AstraZeneca ( AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...